US Peptide Vendor Landscape in 2026

The US market for research peptides lost more vendors between mid-2025 and early 2026 than in the previous five years combined. At least eight major suppliers – including Peptide Sciences, Amino Asylum, Paradigm Peptides, Science.bio, Royal Research, Peptide Tech Labs, American Research Labs, and Unchained Compounds – either shut down voluntarily, were raided by federal agents, or had their operators criminally prosecuted. This page tracks the current state of the US vendor landscape without recommending specific suppliers.

Understanding how the market is structured, where quality data comes from, and what signals actually matter is more important than any vendor ranking list – most of which are affiliate-driven and commercially motivated.

Three tiers of US peptide access

Research peptides in the United States are available through three distinct channels, each with fundamentally different regulatory exposure, pricing structures, and quality assurance standards.

Tier	Description	Typical Cost	Quality Assurance	Regulatory Risk
Grey-market RUO vendors	Online retailers selling peptides labelled “research use only”	$20-80 per vial	Varies dramatically; COA quality ranges from verified batch-specific to fabricated	High and rising
Licensed compounding pharmacies (503A/503B)	Pharmacies compounding peptides under valid prescriptions	$150-500 per month	FDA-regulated facility; USP standards; state pharmacy board oversight	Low for Category 1 compounds
Institutional/academic suppliers	Chemical suppliers (Sigma-Aldrich, Bachem, GenScript) serving research institutions	$200-2,000+ per gram	ISO/GMP-certified manufacturing; full analytical documentation	Negligible

The grey-market tier is where nearly all of the enforcement action, vendor shutdowns, and quality controversies have occurred. Compounding pharmacies operate under a fundamentally different legal framework – for a full explanation of how 503A and 503B compounding works and its current constraints, see our guide to compounded vs branded GLP-1s.

The bottom line: The US peptide market now has three completely separate access tiers with different legal exposure, quality standards, and pricing – treating them as interchangeable is a mistake that can carry real consequences.

Three forces converged between late 2024 and early 2026 to reshape the US vendor landscape. None of them individually would have collapsed the market. Together, they made the grey-market business model untenable for any operator running at scale.

FDA enforcement escalated from letters to raids to prosecutions

In December 2024, the FDA issued warning letters to four grey-market vendors directly: Prime Peptides, Xcel Peptides, SwissChems, and Summit Research. This was significant because the agency had previously focused enforcement on compounding pharmacies rather than the RUO vendor tier. By September 2025, over 50 warning letters had gone out across the broader industry. Our US legality guide covers the full enforcement timeline.

The DOJ’s creation of the Health and Safety Unit within the Criminal Division’s Fraud Section in November 2025 centralised criminal prosecution of FDCA violations. This unit now handles the federal cases that previously sat across multiple divisions – and its 2025 track record included four individuals charged and four corporate enforcement actions.

Pharmaceutical companies opened a litigation front

In March 2024, Eli Lilly filed an International Trade Commission complaint against twelve vendors selling imported tirzepatide. By January 2025, the ITC issued a General Exclusion Order blocking all trademark-infringing tirzepatide imports at the US border – not just against the twelve named respondents, but against any entity importing infringing tirzepatide products. In April 2025, Lilly filed federal lawsuits against telehealth companies distributing unapproved tirzepatide, and in August 2025, Novo Nordisk filed lawsuits against fourteen defendants involved in semaglutide distribution.

For grey-market vendors sourcing from Chinese API manufacturers, the ITC exclusion order cut off a major revenue line overnight. Any vendor still openly selling tirzepatide after January 2025 was operating in direct conflict with an existing federal order.

Quality testing exposed inconsistency at scale

Independent testing platforms – particularly Finnrick Analytics – published quality data that showed some high-profile vendors delivering wildly inconsistent products. Even the largest US vendor by revenue showed a Finnrick rating range spanning from near-failing to perfect scores, with an identity pass rate well below 100% – meaning a measurable percentage of tested samples did not contain the expected peptide at all. For the full vendor-by-vendor record, see our vendor shutdown archive. When quality failures become public and verifiable, the reputational moat that market leaders built through years of community trust can collapse in weeks.

The bottom line: The US grey-market vendor model collapsed because enforcement moved from civil to criminal, pharmaceutical companies deployed litigation as a weapon, and independent testing revealed that quality variation was far wider than marketing suggested.

The single most reliable quality signal for any US research peptide vendor in 2026 is independent third-party testing data – not marketing claims, community reputation, or pricing. Our detailed vendor evaluation guide covers the full methodology for assessing any supplier. The principles below apply specifically to the post-contraction US market.

Independent testing data is the decisive signal

Finnrick Analytics has tested 7,800+ samples from 224 vendors across 15 popular peptides as of mid-2026. The platform uses a 0-10 scoring system based on three components: purity (measured by HPLC), quantity accuracy (divergence from advertised content), and batch identification documentation. Vendors receive an A-E rating for each product, with F reserved for documented, widespread fraud.

What makes Finnrick data useful is not the rating itself but the range. A vendor with a narrow range (such as 7.0-10.0) demonstrates consistent quality control. A vendor with a wide range (such as 3.0-9.5) may be sourcing from multiple suppliers with inconsistent quality, or may have changed API sources during the testing period. The range tells you more than the average.

Red flags specific to the 2026 US market

The post-shutdown landscape created conditions for a specific type of fraud: opportunistic clone websites. Within hours of the Peptide Sciences closure on March 6, 2026, fraudulent domains were registered using near-identical branding, cloned website architectures, and misleading URLs to impersonate the defunct brand. The same pattern occurred after the Amino Asylum and Science.bio closures.

Specific signals that a US vendor is higher risk in 2026:

• Domain registered after March 2026 (check WHOIS) with branding that mimics a defunct vendor
• Still openly listing tirzepatide or semaglutide, which are subject to the ITC General Exclusion Order and active pharmaceutical company litigation
• No Finnrick profile, no verifiable third-party test data, or only vendor-generated COAs with no batch-level tracking
• Before/after imagery or therapeutic claims on product pages – this is the specific marketing behaviour that triggers FDA enforcement action
• Crypto-only payment with no card processing – while some legitimate vendors use crypto alongside cards, crypto-only with no refund mechanism was a common feature of exit scam operations in 2025
• Claims of affiliation with a defunct vendor (“official successor to Peptide Sciences”) – no defunct vendor transferred customer lists or authorised successor branding

The bottom line: In the post-contraction US market, independent testing data from platforms like Finnrick – not vendor marketing, community sentiment, or affiliate recommendations – is the only reliable quality signal.

Before mid-2025, the US grey-market peptide vendor landscape was dominated by a handful of high-volume operations. Peptide Sciences was generating roughly $7.4 million in monthly online sales as of December 2025, according to e-commerce analytics firm Grips Intelligence. Amino Asylum attracted an estimated 400,000+ monthly website visitors. These were not small operations – they were scaled e-commerce businesses with significant infrastructure, customer bases, and revenue.

The closures redistributed demand across a larger number of smaller vendors, many of which had limited operational histories.

Supply chain concentration risk

The majority of grey-market peptides sold in the US are manufactured in China, which accounts for approximately 68% of global peptide API production. US imports of Chinese peptide and hormone compounds reached $328 million in the first three quarters of 2025 alone, roughly double the prior year’s pace. For the full picture of how Chinese supply chains feed the US grey market, see our Chinese peptides trend explainer.

This concentration creates a single point of failure: if the FDA’s Import Alert 66-80 expands, or if Customs and Border Protection increases seizures (151 seizures in Q1 FY2025 alone, exceeding the 132 for all of FY2024), the vendors most dependent on Chinese API supply will be the most immediately affected.

The compounding pharmacy alternative

For compounds on the FDA’s Category 1 bulk drug substances list, licensed compounding pharmacies represent the only fully lawful channel for patient-specific peptide access with a valid prescription. The cost is substantially higher ($150-500 per month versus $20-80 per vial from grey-market vendors), but the regulatory foundation is solid for Category 1 compounds. The Category 1 vs Category 2 explainer covers which compounds currently fall into each classification.

The April 15, 2026 Category 2 removals expanded the pool of compounds eligible for lawful compounding. However, the PCAC meeting scheduled for July 23-24, 2026 will review additional compounds whose final classification is still pending. See the PCAC meeting tracker for current status.

Finnrick Analytics data reveals significant quality variation across US vendors, even among those considered reputable. Across 7,800+ tested samples, purity typically ranges from 98.71% to 99.95% at the 5th to 95th percentile. However, quantity accuracy – whether the vial contains the amount advertised – diverges by up to 52% from the stated value at the 95th percentile. In plain terms, a vial labelled as containing 5mg might contain anywhere from 2.4mg to 7.6mg.

Quality Signal	What It Tells You	Where to Check
Finnrick rating (A-E)	Overall quality composite for a specific product from a specific vendor	finnrick.com/vendors
Rating range	Consistency of quality control; narrow = reliable, wide = variable	Individual vendor pages
Identity pass rate	Percentage of samples confirmed to contain the expected peptide	Vendor pages (% figure)
Quantity accuracy	How closely the actual content matches the labelled amount	Individual test results
Test recency	Whether the vendor is being actively monitored or has only historic data	Past 30 days / past 3 months counts

For a full breakdown of how HPLC purity testing and mass spectrometry identification work, see our HPLC vs mass spectrometry guide.

The bottom line: Quantity accuracy – not just purity – is the quality metric most likely to vary between vendors, and it is routinely ignored by marketing-driven “best vendor” lists that focus exclusively on purity percentages.

Purchasing research peptides in the US is not illegal at the federal level – there is no law that criminalises the act of buying a research chemical. The legal risk sits with the seller, not the buyer. However, the distinction between “purchasing for research” and “purchasing for personal use” is exactly the legal ambiguity that enforcement actions are exploiting on the seller side, and any buyer should understand where the regulatory landscape currently stands.

The RFK reclassification tracker covers the February 27, 2026 announcement that 14 of 19 previously restricted peptides would be considered for reclassification to Category 1. As of mid-2026, no formal Federal Register notice implementing this change has been published. Announcements are not regulations – the legal status of individual compounds is determined by published FDA rules, not press statements. For the full regulatory picture, our regulatory tracker hub links to every jurisdiction-specific and compound-specific analysis.

The US vendor landscape will continue to evolve. Several factors will determine the shape of the market over the next 12-18 months:

• The PCAC July 23-24, 2026 meeting will review the compounding status of several popular compounds including CJC-1295 and ipamorelin – outcomes will directly affect whether these compounds can legally be accessed through compounding pharmacies
• The SAFE Drugs Act, if enacted, would close the “research use only” loophole entirely for compounds biologically identical to FDA-approved drugs
• The 503B bulks proposal published April 30, 2026 (comment deadline June 30, 2026) will determine which compounds outsourcing facilities can produce going forward
• Payment processing constraints continue to tighten – see our payment processors and crypto explainer for how this affects vendor operations and buyer options

For the broader market context – including branded therapeutic approvals, compounding contraction, and grey-market dynamics – see our 2026 market overview.

The bottom line: The US vendor market is in its most uncertain period since grey-market peptide sales began – regulatory, legal, and quality-control pressures are all moving in the same direction simultaneously.